PULM Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States...

Stats
Dzisiejszy wolumen	6 759.00
Średni wolumen	15 388.00
Kapitalizacja rynkowa	7.45M
EPS	$-0.570 ( 2024-04-04 )
Następna data zysków	( $-1.040 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-26	Siegert Michelle	Buy	9 900	Stock Option (Right to Buy)
2023-01-26	Wasilewski Margaret	Buy	11 400	Stock Option (Right to Buy)
2023-01-26	Raad Teofilo David	Buy	34 900	Stock Option (Right to Buy)
2023-01-26	Bazemore Todd	Buy	1 700	Stock Option (Right to Buy)
2023-01-26	Higgins Michael J	Buy	2 436	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 94 transactions
Buy: 13 676 591 \| Sell: 104 308

Pulmatrix Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pulmatrix Inc Finanse

Annual	2023
Przychody:	$7.30M
Zysk brutto:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2023
Przychody:	$7.30M
Zysk brutto:	$5.82M (79.79 %)
EPS:	$-3.87

FY	2022
Przychody:	$6.07M
Zysk brutto:	$4.53M (74.55 %)
EPS:	$-5.43

FY	2021
Przychody:	$5 169.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.00745

Financial Reports:

No articles found.

Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.